New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
18:48 EDTNPSP, LMT, KKD, GWRE, SHPG, ZQKOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guidewire (GWRE), up over 1% after reporting better than expected Q3 results and giving guidance on its conference call. ALSO HIGHER: Lockheed Martin (LMT), up fractionally after being awarded a $914.7M Space Fence contract. DOWN AFTER EARNINGS: Quiksilver (ZQK), down 30%... Krispy Kreme Doughnuts (KKD), down 10.5%. ALSO LOWER: NPS Pharmaceuticals (NPSP), down almost 1% after disclosing in a filing that it has not had any communication with Shire (SHPG) concerning a purported acquisition offer.
News For GWRE;LMT;ZQK;KKD;NPSP;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 27, 2015
12:36 EDTSHPGOn The Fly: Midday Wrap
Subscribe for More Information
10:29 EDTSHPGBioMarin rises amid takeover speculation, price target raises
The shares of BioMarin (BMRN) are climbing after a blog reported last night that Shire (SHPG) is considering offering to acquire the company. Meanwhile, analysts at UBS and Deutsche raised their price targets for the orphan drug maker, in part due to the possibility of a takeover. WHAT'S NEW: "Well-informed" sources are saying that Shire recently approached BioMarin about a merger deal, Ben Harrington of the blog Betaville reported last night. It's not clear how far the talks have progressed, but Morgan Stanley and Lazard are advising Shire on a deal that could be worth $65B, the blog added. ANALYSTS' TAKE: The recent acquisition of Pharmacyclics (PCYC) by AbbVie (ABBV) shows that drug companies need to acquire products and pipelines, UBS analyst Andrew Peters wrote in a note to investors earlier today. Given its diversified pipeline of orphan products and multi-billion revenue potential, BioMarin is among the most attractive targets in the sector, according to Peters. As a result, the analyst finds it appropriate to assign premiums to drug companies for their strategic value. Additionally, the analyst has become more upbeat on several of BioMarin's pipeline drugs and on its R&D capabilities. He raised his price target on the stock to $136 from $112 and kept a Buy rating on the shares. Also upbeat on the stock was Deutsche Bank analyst Robyn Karnauskas. BioMarin's top four pipeline drugs have 25%-50% chances of succeeding, but not everything in the company's pipeline needs to work for it to obtain an M&A premium, the analyst stated in a note to investors today. She believes that BioMarin can be acquired for $194-$271 per share in the next year, depending on the data from several of its drug candidates. The analyst raised her price target on the name to $140 from $90 and kept a Buy rating on the stock. PRICE ACTION: In early trading, BioMarin jumped 13.5% to $130. PRICE ACTION: In early trading, BioMarin climbed 13.5% to $130.
07:38 EDTSHPGBioMarin price target raised to $140 from $90 at Deutsche Bank
Subscribe for More Information
07:08 EDTZQKQuiksilver names president Pierre Agnes as CEO; Andy Mooney no longer with co.
Subscribe for More Information
05:58 EDTSHPGBioMarin price target raised to $136 from $112 at UBS
UBS analysts Andrew Peters and Matthew Roden raised their price target for BioMarin (BMRN) shares to $136 saying investors "are still well served" to buy the stock despite the recent outperformance and talk of a bubble in the Biotech space. The analysts view BioMarin as among the most attractive takeover targets in biotech. They add the company's 2015 is filled with pipeline catalyst and keep a Buy rating on the name. The target raise at UBS comes after Ben Harrington last night, former M&A and Markets Editor at the Daily Telegraph and current editor of the blog Betaville, said that Shire (SHPG) is weighing a takeover of BioMarin. Shares of the orphan drug maker closed yesterday down 7c to $115.55 and are trading up $8.95 to $124.50 in pre-market trading.
March 26, 2015
19:30 EDTSHPGBioMarin up 4% after blog says Shire weighing takeover
BioMarin (BMRN) is trading up over 4% in the after-hours after Ben Harrington, former M&A and Markets Editor at the Daily Telegraph and current editor of the blog Betaville, said that Shire (SHPG) is weighing a takeover of BioMarin. Reference Link
11:13 EDTSHPGBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 25, 2015
06:34 EDTLMTLockheed Martin likely to miss out on portion of F-35 incentive fee, WSJ says
Subscribe for More Information
March 24, 2015
08:56 EDTGWREGuidewire BillingCenter selected by La Capitale General Insurance
Subscribe for More Information
March 23, 2015
10:24 EDTLMTRADA Electronic selected by Lockheed Martin for laser weapon research projects
Subscribe for More Information
09:45 EDTSHPGUBS to hold a field trip
Subscribe for More Information
09:37 EDTSHPGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:13 EDTLMTBofA/Merrill airlines/aerospace analysts hold analyst/industry conference call
Subscribe for More Information
08:01 EDTLMTBofA/Merrill industrials/EU autos analysts hold analyst/industry conference call
Analysts provide a discussion of the key takeaways from the recently held Global Industrials & European Autos Conference on an Analyst/Industry conference call. to be held on March 23 at 10 am.
07:36 EDTSHPGPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
07:35 EDTLMTLockheed working to resolve technical error with GPS satellites, Reuters says
Subscribe for More Information
07:01 EDTGWREGuidewire's InsuranceSuite selected by Hastings Direct
Subscribe for More Information
March 20, 2015
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use